Sunitinib Malate
舒尼替尼是一种口服的小分子多靶点受体酪氨酸激酶(RTK)抑制剂,用于治疗肾细胞癌(RCC)和对伊马替尼耐药的胃肠间质瘤(GIST)。
全国免运费, 顺丰次日达
重要通知:仅供研究使用。我们不向患者销售。
重要通知:仅供研究使用。我们不向患者销售。
Discription | Sunitinib is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). | |||||
---|---|---|---|---|---|---|
Targets |
|
|||||
Cell Research |
|
目录号 | A10880 |
---|---|
分子式 | C22H27FN4O2.C4H6O5 |
分子量 | 532.6 |
CAS号 | 341031-54-7 |
SMILES | CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C.C([C@@H](C(=O)O)O)C(=O)O |
其他名称 | SU-11248 |
储存条件 | Store lyophilized at -20ºC, keep desiccated. |
In vitro (25°C) | DMSO | 13 mg/mL (24.41 mM) | |
Water | Insoluble | ||
Ethanol | Insoluble | ||
In vivo | 4% DMSO+30% PEG 300+ddH2O | 1 mg/mL | |
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.1 mM | 18.78 mL | 93.88 mL | 187.76 mL |
0.5 mM | 3.76 mL | 18.78 mL | 37.55 mL |
1 mM | 1.88 mL | 9.39 mL | 18.78 mL |
5 mM | 0.38 mL | 1.88 mL | 3.76 mL |
Calculate the dilution required to prepare a stock solution. This equation is commonly abbreviated as: C1V1 = C2V2